Inversago

History

2023: Novo Nordisk bought Inversago for $1.07 billion

On August 10, 2023, Danish pharmaceutical company Novo Nordisk announced an agreement to acquire Canadian obesity drug developer Inversago Pharma. The transaction amount is approximately $1 billion.

Inversago's assets include the drug INV-202, a reverse CB1 agonist for oral administration. It is noted that CB1 plays an important role in the regulation of appetite. Initial stage trials (phase 1b) have shown the efficacy of the drug INV-202 in the fight against obesity. During the 28-day test period, patients treated with the drug showed clinically significant and progressive weight loss - an average of 3.5 kg compared to an average increase of 0.45 kg in patients treated with placebo.

Danish pharmaceutical company Novo Nordisk announces agreement to acquire Inversago Pharma

The acquisition of Inversago will further expand our range of clinical developments in obesity and related disorders, "said Martin Holst Lange, executive vice president of development at Novo Nordisk.

Inversago has 22 employees in Canada. It is said that the amount of the transaction with Novo Nordisk will amount to $1.075 billion in cash if "certain stages of development and commercial activities are achieved." The merger is scheduled to be completed by the end of 2023, subject to the necessary regulatory approvals.

Novo Nordisk intends to explore the potential of INV-202 in relation to obesity and complications associated with this ailment. The acquisition of Inversago is expected to help in bringing to market medicines that will help improve the quality of life of people suffering from said chronic disease. Inversago is also developing other treatments for metabolic and fibrous disorders.^[1]

Notes